What the trial was testing
The HGB-206 enrolled 54 patients with sickle cell disease. The study was sponsored by Genetix Biotherapeutics Inc. and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was an early-stage trial — researchers are still confirming safety and getting an early look at how well the treatment works. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
All 25 patients stopped having severe pain crises after gene therapy.
The New England journal of medicine · 2022 · NCT02140554
These findings — that everyone who could be evaluated had complete resolution of severe pain episodes — were published in the The New England journal of medicine and represent the headline result of the study.
Researchers tracked outcomes across 54 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with sickle cell disease, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
This gene therapy (now called Lyfgenia) was FDA-approved in December 2023 for adults and children 12 and older with sickle cell disease and a history of pain crises. It's a one-time treatment available at specialized centers. Talk to your doctor about whether you qualify and what the treatment involves.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open sickle cell disease trials
Hemoglobin Disorders in Egypt: Sickle Cell Disease Ain Shams University Institutional Registry
This is a retrospective descriptive study to create an institutional registry that will continue as a prospective follow-up non-intervention study that will be carried out at Hematology Oncology and BMT Department, Children's Hospital, Ain-Shams University, Cairo, Egypt.
T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
The purpose of this study is to evaluate what effect, if any, mismatched unrelated volunteer donor and/or haploidentical related donor stem cell transplant may have on severe sickle cell disease and other transfusion dependent anemias. By using mismatched unrelated volunteer donor and/or haploidentical related donor stem cells, this study will increase the number of patients who can undergo a stem cell transplant for their specified disease. Additionally, using a T-cell depleted approach should reduce the incidence of graft-versus-host disease which would otherwise be increased in a mismatched transplant setting.